nitrites has been researched along with Idiopathic Parkinson Disease in 29 studies
Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although alpha-synuclein is the main structural component of the insoluble filaments that form Lewy bodies in Parkinson disease (PD), its physiological function and exact role in neuronal death remain poorly understood." | 3.73 | Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. ( Chung, KC; Kim, J; Lee, CH; Lee, HJ; Lee, ST; Oh, YJ; Paik, SR; Park, SM; Sung, JY; Um, JW, 2005) |
| "To investigate whether nitric oxide (NO) plays a role in degenerative neurologic disease (DND), we measured nitrite, nitrate and cyclic GMP in cerebrospinal fluid (CSF) samples from patients with Parkinson's disease (PD), spinocerebellar ataxia (SCA) and amyotrophic lateral sclerosis (ALS)." | 3.69 | Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic diseases. ( Ikeda, M; Miyatake, T; Murota, S; Sato, I; Yuasa, T, 1995) |
| "Treatment with mangiferin and 7-NI significantly increases locomotor parameters in 6-OHDA lesioned rats." | 1.72 | Effects of mangiferin and its combination with nNOS inhibitor 7-nitro-indazole (7-NI) in 6-hydroxydopamine (6-OHDA) lesioned Parkinson's disease rats. ( Chaudhary, MJ; Nath, R; Pal, R; Tiwari, PC, 2022) |
| "Parkinson's disease is a neurodegenerative disorder that affects the central nervous system and is mainly characterized by the loss of dopaminergic neurons and pro-oxidant mechanisms." | 1.56 | Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations. ( Aragão Catunda Junior, FE; Basto Souza, R; da Cunha Ferreira, NM; de Sousa Dos Reis, TD; Hardy Lima Pontes, N; Maranguape Silva da Cunha, R; Moreira Vasconcelos, CF; Vasconcelos Aguiar, LM, 2020) |
| "In brains from victims of Parkinson's disease, a nitrosyl species, identified as nitrosyl hemoglobin, has been observed in substantia nigra." | 1.30 | Applications of electron paramagnetic resonance spectroscopy to study interactions of iron proteins in cells with nitric oxide. ( Ananda Inalsingh, V; Cammack, R; Hughes, MN; Shergill, JK, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (20.69) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 10 (34.48) | 24.3611 |
| 2020's | 4 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Tiwari, PC | 1 |
| Chaudhary, MJ | 1 |
| Pal, R | 1 |
| Nath, R | 1 |
| Tiwari, S | 1 |
| Gupta, P | 1 |
| Singh, A | 1 |
| Chaturvedi, S | 1 |
| Wahajuddin, M | 1 |
| Mishra, A | 2 |
| Singh, S | 3 |
| Datta, I | 1 |
| Mekha, SR | 1 |
| Kaushal, A | 1 |
| Ganapathy, K | 1 |
| Razdan, R | 1 |
| Moreira Vasconcelos, CF | 1 |
| da Cunha Ferreira, NM | 1 |
| Hardy Lima Pontes, N | 1 |
| de Sousa Dos Reis, TD | 1 |
| Basto Souza, R | 1 |
| Aragão Catunda Junior, FE | 1 |
| Vasconcelos Aguiar, LM | 1 |
| Maranguape Silva da Cunha, R | 1 |
| Leonoudakis, D | 1 |
| Rane, A | 1 |
| Angeli, S | 1 |
| Lithgow, GJ | 1 |
| Andersen, JK | 1 |
| Chinta, SJ | 1 |
| Milanese, C | 1 |
| Tapias, V | 1 |
| Gabriels, S | 1 |
| Cerri, S | 1 |
| Levandis, G | 1 |
| Blandini, F | 1 |
| Tresini, M | 1 |
| Shiva, S | 1 |
| Greenamyre, JT | 1 |
| Gladwin, MT | 1 |
| Mastroberardino, PG | 1 |
| de Araújo, DP | 1 |
| Nogueira, PCN | 1 |
| Santos, ADC | 1 |
| Costa, RO | 1 |
| de Lucena, JD | 1 |
| Jataí Gadelha-Filho, CV | 1 |
| Lima, FAV | 1 |
| Neves, KRT | 1 |
| Leal, LKAM | 1 |
| Silveira, ER | 1 |
| Viana, GSB | 1 |
| Rukmangathen, R | 1 |
| Yallamalli, IM | 1 |
| Yalavarthi, PR | 1 |
| Jayaraj, RL | 1 |
| Beiram, R | 1 |
| Azimullah, S | 1 |
| Meeran, MFN | 1 |
| Ojha, SK | 1 |
| Adem, A | 1 |
| Jalal, FY | 1 |
| Gupta, SP | 1 |
| Kamal, R | 1 |
| Mishra, SK | 1 |
| Singh, MK | 1 |
| Shukla, R | 3 |
| Singh, MP | 1 |
| Shukla, S | 1 |
| Rajaei, Z | 1 |
| Hosseini, M | 1 |
| Alaei, H | 1 |
| Barros, AS | 1 |
| Crispim, RYG | 1 |
| Cavalcanti, JU | 1 |
| Souza, RB | 1 |
| Lemos, JC | 1 |
| Cristino Filho, G | 1 |
| Bezerra, MM | 1 |
| Pinheiro, TFM | 1 |
| de Vasconcelos, SMM | 1 |
| Macêdo, DS | 2 |
| de Barros Viana, GS | 1 |
| Aguiar, LMV | 1 |
| Rojanathammanee, L | 1 |
| Murphy, EJ | 1 |
| Combs, CK | 1 |
| Wersinger, C | 1 |
| Sidhu, A | 1 |
| Li, G | 1 |
| Cui, G | 1 |
| Tzeng, NS | 1 |
| Wei, SJ | 1 |
| Wang, T | 2 |
| Block, ML | 2 |
| Hong, JS | 2 |
| Zhang, W | 2 |
| Pei, Z | 1 |
| Miller, DS | 1 |
| Wu, X | 1 |
| Wilson, B | 1 |
| Zhou, Y | 1 |
| Zhang, J | 1 |
| Sung, JY | 1 |
| Park, SM | 1 |
| Lee, CH | 1 |
| Um, JW | 1 |
| Lee, HJ | 1 |
| Kim, J | 1 |
| Oh, YJ | 1 |
| Lee, ST | 1 |
| Paik, SR | 1 |
| Chung, KC | 1 |
| Das, T | 1 |
| Ravindran, A | 1 |
| Chaturvedi, RK | 1 |
| Shukla, Y | 1 |
| Agarwal, AK | 1 |
| Dikshit, M | 3 |
| Lee, SJ | 1 |
| Kim, DC | 1 |
| Choi, BH | 1 |
| Ha, H | 1 |
| Kim, KT | 1 |
| Rajani, M | 1 |
| Srivastava, N | 2 |
| Barthwal, MK | 2 |
| Aguiar, LM | 1 |
| Vasconcelos, SM | 1 |
| Oliveira, AA | 1 |
| de Sousa, FC | 1 |
| Viana, GS | 1 |
| Kuiper, MA | 1 |
| Visser, JJ | 1 |
| Bergmans, PL | 1 |
| Scheltens, P | 1 |
| Wolters, EC | 1 |
| Qureshi, GA | 1 |
| Baig, S | 1 |
| Bednar, I | 1 |
| Södersten, P | 1 |
| Forsberg, G | 1 |
| Siden, A | 1 |
| Ikeda, M | 1 |
| Sato, I | 1 |
| Yuasa, T | 1 |
| Miyatake, T | 1 |
| Murota, S | 1 |
| Cammack, R | 1 |
| Shergill, JK | 1 |
| Ananda Inalsingh, V | 1 |
| Hughes, MN | 1 |
| Nag, D | 1 |
| Seth, PK | 1 |
| Srimal, RC | 1 |
| LaVoie, MJ | 1 |
| Hastings, TG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in the Context of Psychometric and Biochemical Measures[NCT05696665] | 120 participants (Anticipated) | Interventional | 2022-07-05 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 other studies available for nitrites and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Effects of mangiferin and its combination with nNOS inhibitor 7-nitro-indazole (7-NI) in 6-hydroxydopamine (6-OHDA) lesioned Parkinson's disease rats.
Topics: Animals; Male; Nitrites; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2022 |
4-Phenylbutyrate Mitigates the Motor Impairment and Dopaminergic Neuronal Death During Parkinson's Disease Pathology via Targeting VDAC1 Mediated Mitochondrial Function and Astrocytes Activation.
Topics: alpha-Synuclein; Animals; Astrocytes; bcl-2-Associated X Protein; Calcium; Caspase 3; Cytochromes; D | 2022 |
Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Alanine Transaminase; Anim | 2020 |
Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Disease Models, Animal; Eugenol; Glutathione; Levodop | 2020 |
Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Azepines; Blotting, Western; Cell Survival; Heterocyc | 2017 |
Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease.
Topics: Animals; Antioxidants; Behavior, Animal; Cell Respiration; Cell Survival; Cytoprotection; Disease Mo | 2018 |
Aspidosperma pyrifolium Mart: neuroprotective, antioxidant and anti-inflammatory effects in a Parkinson's disease model in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aspidosperma; Behavior, Animal; Corpus Striatum; Di | 2018 |
Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Brain; Catalase; Catalepsy; Chitosan; Chl | 2019 |
Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Antioxidants; Brain; Catalase; Cyclooxygenase 2; Cytokines; Disease Models | 2019 |
Association of Polymorphism of Neuronal Nitric Oxide Synthase Gene with Risk to Parkinson's Disease.
Topics: Aged; Case-Control Studies; Exons; Female; Gene Frequency; Genetic Association Studies; Genetic Pred | 2016 |
ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Antioxidants; Ataxia; Axons; Behavior, Animal; Brain; Cell Nucleus; Diseas | 2016 |
Effects of crocin on brain oxidative damage and aversive memory in a 6-OHDA model of Parkinson's disease.
Topics: Animals; Antioxidants; Carotenoids; Cerebral Cortex; Disease Models, Animal; Glutathione Peroxidase; | 2016 |
Impact of the Chronic Omega-3 Fatty Acids Supplementation in Hemiparkinsonism Model Induced by 6-Hydroxydopamine in Rats.
Topics: Animals; Apomorphine; Biogenic Monoamines; Brain; Dietary Supplements; Disease Models, Animal; Fatty | 2017 |
Recent discoveries about diabetes.
Topics: Adipose Tissue, Brown; Adolescent; Alzheimer Disease; Child; Child, Preschool; Diabetes Mellitus; En | 2009 |
Expression of mutant alpha-synuclein modulates microglial phenotype in vitro.
Topics: alpha-Synuclein; Animals; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Humans; Interleukin-6; Lyso | 2011 |
Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants.
Topics: alpha-Synuclein; Blotting, Western; Cell Death; Dopamine; Humans; Hydrogen Peroxide; Mutation; Nerve | 2003 |
Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage.
Topics: Animals; Astrocytes; Cell Death; Cells, Cultured; Coculture Techniques; Dextromethorphan; Dinoprosto | 2005 |
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Topics: alpha-Synuclein; Animals; Astrocytes; Brain; Cells, Cultured; Dinoprostone; Dopamine; Embryo, Mammal | 2005 |
Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Catalytic Dom | 2005 |
Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease.
Topics: Animals; Brain; Female; Lipopolysaccharides; Male; Neurodegenerative Diseases; NG-Nitroarginine Meth | 2005 |
Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death.
Topics: Animals; Apoptosis; Catechin; Cell Death; Cell Line; Cell Survival; Coculture Techniques; Dopamine; | 2006 |
Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease.
Topics: Female; Free Radicals; Humans; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Nitrates; Nit | 2006 |
CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Behavior, Animal; Biogenic Monoamines; Caffeine; Disease Mo | 2008 |
Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients.
Topics: Aged; Alzheimer Disease; Atrophy; Dementia; Female; Humans; Male; Middle Aged; Nerve Degeneration; N | 1994 |
Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease.
Topics: Aged; Arginine; Female; Humans; Levodopa; Male; Middle Aged; Nitric Oxide; Nitrites; Parkinson Disea | 1995 |
Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic diseases.
Topics: Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Cyclic GMP; Female; Humans; Male; Middle Aged; Nerv | 1995 |
Applications of electron paramagnetic resonance spectroscopy to study interactions of iron proteins in cells with nitric oxide.
Topics: Animals; Bacteria; Cysteine; Electron Spin Resonance Spectroscopy; Food Preservation; Hemeproteins; | 1998 |
Polymorphonuclear leukocyte nitrite content and antioxidant enzymes in Parkinson's disease patients.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neutrophils; Nitric Oxide; Nitric Oxide Synthase; Ni | 1999 |
Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcohol Dehydrogenase; Antioxidants; Apoptosis; Catala | 1999 |